Health Care

Analyst Price Target Estimates: Abbott Laboratories (NYSE:ABT) , Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

0 7

Abbott Laboratories (NYSE:ABT) initiated the shares trading at $41.05 and showed positive change of +0.20% while the stock’s final trade was registered at $ 40.98. However, its previous closing price was seen at $40.90. The stock negotiated total number of 6.4 million shares as compared to 3 months average volume of 9.29 million shares.

The stock price demonstrated downbeat change from its 50 day moving average of 42.08 and had been down from its 200 Day Moving Average of 41.39.

Brokerage Recommendations:

Shares of Abbott Laboratories (NYSE:ABT) climbed +0.20% and ended at $40.98 greater than previous closing price of $40.90. The total 6.4 million shares were bought and sold throughout the most recent trading session less than average volume of 9.29 million shares.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) initiated the shares trading at $70.05 and showed negative change of -6.47% while the stock’s final trade was registered at $ 65.51. However, its previous closing price was seen at $70.04. The stock negotiated total number of 696.57 thousand shares as compared to 3 months average volume of 591.23 thousand shares.

The stock price demonstrated downbeat change from its 50 day moving average of 69.97 and had been up from its 200 Day Moving Average of 64.46.

Brokerage Recommendations:

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) declined -6.47% and ended at $65.51 smaller than previous closing price of $70.04. The total 696.57 thousand shares were bought and sold throughout the most recent trading session more than average volume of 591.23 thousand shares.

About the author / 

Leave a reply

Your email address will not be published. Required fields are marked *

Advirtisement

About Us

WSnews4investors is the influential source for financial news and Opinion Company with content which delivered over the Internet. WSnews4investors is a dynamic and innovative financial media outlet that empowers investors with high-quality, unique content that is coveted by Wall Street’s traders.

Newsletter